MDGL Quote, Financials, Valuation and Earnings

Altimmune has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -391500%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Altimmune's return on equity of -62.28%.

Madrigal Pharmaceuticals has a consensus price target of $423.21, signalling upside risk potential of 22.68%. On the other hand Altimmune has an analysts' consensus of $17.60 which suggests that it could grow by 321.05%. Given that Altimmune has higher upside potential than Madrigal Pharmaceuticals, analysts believe Altimmune is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison Altimmune has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.709%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Altimmune quarterly revenues of $5K. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Altimmune's net income of -$19.6M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 23.69x versus 15,089.22x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of 26.7%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Madrigal Pharmaceuticals has a consensus price target of $423.21, signalling upside risk potential of 22.68%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Regeneron Pharmaceuticals has higher upside potential than Madrigal Pharmaceuticals, analysts believe Regeneron Pharmaceuticals is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 23.69x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of 4.19%. Madrigal Pharmaceuticals's return on equity of -49.57% beat TG Therapeutics's return on equity of 19.78%.

Madrigal Pharmaceuticals has a consensus price target of $423.21, signalling upside risk potential of 22.68%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that Madrigal Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Madrigal Pharmaceuticals is more attractive than TG Therapeutics.

Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than TG Therapeutics's net income of $5.1M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 23.69x versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -49.57% beat Viking Therapeutics's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $423.21, signalling upside risk potential of 22.68%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 185.37%. Given that Viking Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Viking Therapeutics quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 23.69x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.